Jan 28, 2025 / 01:00PM GMT
Christoffer Rosenblad - Xvivo Perfusion AB - Chief Executive Officer
Welcome to XVIVO's earning call for the fourth quarter of 2024 and the full year 2024 as well. I want to start this meeting with XVIVO's purpose and vision that nobody should die waiting for an organ. And you see one of our patients here on the front page, Alex from Australia.
During 2024, we estimate that XVIVO's products and services have contributed to more than 12,000 transplants globally. And that means that 12,000 patients got the chance to prolong life and a better life quality.
And I want to take the moment end of the year to also thank all of you who invested in XVIVO, for financing development of the groundbreaking technology that we now take to market and that enable all of those 12,000 patients to be saved every year. And I hope in the future there will be many more.
So, with that, we turn to the first slide of the presentation, which is today's presenter, and they are me, Christoffer Rosenblad, I'm the CEO of the company. And we have also Kristoffer Nordström, CFO of the company. And we can jump
Q4 2024 Xvivo Perfusion AB Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
